Developmental therapeutics in childhood cancer. A perspective from the Children's Oncology Group and the US Food and Drug Administration.

M L Bernstein, G H Reaman, S Hirschfeld

Journal: Hematology/oncology clinics of North America 2002;15(4):631-55

PMID: 11676277

Full Text on Elsevier Science View on PubMed

Abstract

Drug development in pediatric oncology has been reviewed, concentrating on overall development issues and COG studies of cytotoxic compounds. A variety of interesting molecules with more specific targeting are becoming available. The challenges that remain include the availability of such compounds for pediatric trial and their study in a timely fashion, and the subsequent incorporation of the new agents into more up-front regimens, with the ultimate shared goal of curing more children with less toxicity.

Address: Service of Hematology-Oncology, Sainte-Justine Hospital, Department of Pediatrics, University of Montreal, Montreal, Québec, Canada.

DOI: 10.1016/s0889-8588(05)70240-9

Link outs

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0889...

MeSH Terms: Adolescent, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Clinical Trials, Phase I as Topic, Drug Design, Ethics, Medical, Forms and Records Control, Humans, Infant, Liver, Maximum Tolerated Dose, Multicenter Studies as Topic, Neoplasms, Patient Selection, Safety, Severity of Illness Index, Treatment Outcome, United States, United States Food and Drug Administration